Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1102685 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clostridioides difficile infection and recurrence in cancer patients (CIRCA): a multicentre, international study.
Int J Infect Dis
January 2025
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia; Department of Infectious Diseases and National Center for Infection, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC, Australia.
Objectives: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality.
Methods: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish hospital. Logistic regression analyses were performed.
Loop Ileostomy With Colonic Lavage: Case Report of an Alternative to Total Colectomy in the Setting of Fulminant Clostridium difficile Colitis.
Cureus
November 2024
General Surgery, Broward Health and South Florida Surgical Specialists, Fort Lauderdale, USA.
Fulminant colitis is a severe and potentially life-threatening form of associated bacterial disease leading to inflammation and damage to the colon. Complications such as toxic megacolon, sepsis, and multi-organ failure commonly occur in individuals with compromised immune systems and recent antibiotic use. Management of colitis involves optimization of fluid and electrolyte balance, and elimination of bacteria commonly by administering vancomycin or fidaxomicin.
View Article and Find Full Text PDFObjective: One of the main problems with Clostridioides difficile infection (CDI) is its tendency to recur. The objective of the study is to analyze which factors in the clinical management of CDI favor recurrence.
Methods: This is a retrospective study conducted at the Hospital Universitario Príncipe de Asturias on cases of CDI between January 2021 and June 2023.
Fidaxomicin resistance in : a systematic review and predictive modeling with RNA polymerase binding sites.
Antimicrob Agents Chemother
December 2024
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
Fidaxomicin (FDX), an RNA polymerase (RNAP) inhibitor antibiotic, is a guideline-recommended therapy for infection. Mutations associated with reduced FDX minimum inhibitory concentrations (MICs) have been identified. However, the molecular characterization of these mutations on FDX binding and the development of FDX resistance have not been studied.
View Article and Find Full Text PDFMicrobiota restoration for recurrent Clostridioides difficile infection.
Panminerva Med
December 2024
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA -
Article Synopsis
- * Testing for CDI remains complicated due to the high sensitivity of PCR, leading to false positives, and the limited sensitivity of toxin assays, complicating accurate diagnosis.
- * Treatment prefers fidaxomicin for recurrent CDI due to its lower disruption of the microbiota compared to broad-spectrum antibiotics like vancomycin, while new FDA-approved therapies and fecal microbiota transplantation (FMT) show promise in managing this infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!